US FDA accepts QRxPharma's NDA for review for pain drug MoxDuo IR
This article was originally published in Scrip
Executive Summary
The US FDA has accepted for review QRxPharma's new drug application (NDA) for MoxDuo IR as a treatment for moderate to severe acute pain and has set 25 June 2012 as the Prescription Drug User Fee Act action date, the firm said.